EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐Term Outcomes of Patients Who Receive a Liver Transplant for Hepatitis B With Limited Use of Hepatitis B Immunoglobulin

Giovanni A Roldan iD, Erica Loon iD, John Lake iD, Nicholas Lim iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Giovanni A Roldan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Immunoglobulins, Hepatitis B virus, Postoperative Complications. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma (HCC). Post‐transplant HBV reinfection represents an important post‐liver transplantation (LT) complication, which can result in death or graft loss. Hepatitis B immunoglobulin (HBIG) has proven effective in preventing reinfection; however, its high cost and patient inconvenience underscore the need for alternative strategies. In this study, we evaluated the long‐term outcomes of HBV‐positive LT recipients who received very short‐term HBIG immunoprophylaxis combined with life‐long antiviral therapy. We conducted a single‐center, retrospective cohort study of patients who underwent LT for HBV between 2002 and 2022. Viremic patients received an intraoperative and six consecutive daily doses of HBIG, while non‐viremic patients received two doses only post‐LT, along with long‐term antiviral therapy. The primary outcome was HBV reinfection. Secondary outcomes included death‐censored graft survival and overall survival. Seventy‐six patients were included. Of these, only three experienced HBV reinfection over the study period. The cumulative incidence of reinfection at 1, 12, 24, and 48 months was observed to be 1.37%, 2.76%, 2.76%, and 2.76%, respectively. The 1‐, 3‐, and 5‐year death‐censored graft survival rates were 94%, 94%, and 92%, respectively. The 1‐, 3‐, and 5‐year overall survival rates were 92%, 92%, and 85%, respectively. A very short‐term HBIG protocol produced excellent post‐transplant outcomes for HBV‐positive LT recipients, with very low rates of HBV reinfection and excellent graft and overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationImmunoglobulinsHepatitis B virusPostoperative ComplicationsGraft RejectionAntiviral AgentsHepatitis B, ChronicHepatitis BHumansMaleFemaleRetrospective StudiesMiddle AgedFollow-Up StudiesGraft SurvivalSurvival RatePrognosisAdultRisk FactorsAged

Substanzen

Immunoglobulinshepatitis B hyperimmune globulinAntiviral Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medicine, Gastroenterology and Hepatology, University of Rochester, Rochester, New York, USA.

ORCID-Profile: Giovanni A Roldan, Erica Loon, John Lake, Nicholas Lim

Zitieren

APA

Roldan, G. A., Loon, E., Lake, J., & Lim, N. (2025). Long‐Term Outcomes of Patients Who Receive a Liver Transplant for Hepatitis B With Limited Use of Hepatitis B Immunoglobulin. Clinical Transplantation. https://doi.org/10.1111/ctr.70391

Vancouver

Roldan GA, Loon E, Lake J, Lim N. Long‐Term Outcomes of Patients Who Receive a Liver Transplant for Hepatitis B With Limited Use of Hepatitis B Immunoglobulin. Clinical Transplantation. 2025. doi:10.1111/ctr.70391

BibTeX
@article{Roldan2025,
  author = {Roldan, Giovanni A and Loon, Erica and Lake, John and Lim, Nicholas},
  title = {Long‐Term Outcomes of Patients Who Receive a Liver Transplant for Hepatitis B With Limited Use of Hepatitis B Immunoglobulin},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70391}
}
Kostenlos starten →